… This review summarizes the latest market trends and outlines the preeminent antibody
engineering technologies used in the development of therapeutic antibody drugs, such as …

… and interpretation in drug development for both small molecule drugs and biotherapeutics. …
during drug discovery and development for both small-molecule drugs and biotherapeutics. …

… In this review, we highlight the emerging trends and approaches in protein drug
development by using examples of therapeutic proteins approved by the US Food and Drug …

… other drugs for the treatment of TB infections. The use of RIF in combination with PZA/INH
led to the establishment of short therapy courses, which reduced routine TB treatment from 1 …

… weeks of therapy, 6 months of treatment with currently available drugs is required to … therapy
including the following: drug intolerance and toxicities, with the resultant need for treatment …

… The two drugs with the shortest clinical development time … cancer treatment) and elexacaftor
(a cystic fibrosis treatment). … and the triple combination therapy including this drug, Trikafta, …

… currently problematic states of both drug development and therapy. … drug therapies and the
promulgation of evidence-based best practices. Development of evidence-based therapeutic …

… as adjunctive therapy for shortening duration of therapy, preventing permanent lung injury,
and improving treatment outcomes of MDR tuberculosis. We discuss the HDT development …

… towards the development of drugs that disrupt or normalize this process for cancer therapy.
Some … In this review article, we summarize the clinical use of small molecules and therapeutic …

… that are safe, effective against resistant strains, are able to shorten the course of treatment, …
with antiretroviral drugs. Drugs that are currently in phase 3 development are moxifloxacin …